Greenstone Biosciences Receives NIH Award to Advance AI-Driven Drug Discovery for DMD Cardiomyopathy

Award supports an iPSC and AI-driven drug discovery program targeting the leading cause of death in DMD patients Greenstone Biosciences, a biote...

August 10, 2026 | Monday | News
FDA Grants Accelerated Approval to Replimune’s Tudriqev for Advanced Melanoma

The U.S. Food and Drug Administration granted accelerated approval to Tudriqev (vusolimogene oderparepvec-wtpg), a genetically modified oncolytic viral t...

August 10, 2026 | Monday | News
Biogen Completes Acquisition of RayThera to Strengthen Immunology Pipeline

Biogen Inc. announced the completion of the acquisition of RayThera Inc., a privately held biotechnology company focused on discovering and developing sm...

August 10, 2026 | Monday | News
Bavarian Nordic Expands MVA-BN Approval to Children Aged 2 and Older in EU

MVA-BN approval expanded to include children aged 2 to less than 12 years for protection against mpox, smallpox and disease caused by vaccinia virus A...

August 10, 2026 | Monday | News
Bone Biologics Advances Targeted Bone Regeneration with the NELL-1 Platform

    Bone Biologics is developing a targeted approach to bone regeneration through its proprietary NELL-1 platform, designed to address the li...

August 10, 2026 | Monday | Interaction
Basilea Secures Additional BARDA Funding to Advance Oral Antibiotic for Complicated UTIs

Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bac...

August 06, 2026 | Thursday | News
Medicus Pharma Receives UAE IND Clearance for Phase 2a Endometriosis Study of Teverelix

Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a biotech/life sciences company focused on advancing the clinica...

August 04, 2026 | Tuesday | News
Novartis Secures FDA Approval for Pluvicto in Earlier-Stage Metastatic Prostate Cancer

Pluvicto now approved across PSMA+ metastatic prostate cancer, nearly doubling eligible patient population PSMAddition updated results show Pluvicto r...

August 04, 2026 | Tuesday | News
From Documentation to Detection: How AI Is Changing the APP Role

Artificial intelligence is transforming the role of advanced practice providers (APPs) by streamlining documentation, simplifying clinical workfl...

August 03, 2026 | Monday | Interaction
NeuroPace to Work with FDA After PMA Supplement for IGE Indication Receives Non-Approvable Letter

-- Company received communication from FDA indicating that the PMA Supplement for idiopathic generalized epilepsy is not approvable in its current form...

July 30, 2026 | Thursday | News
Verastem Oncology Dosed First Patient in Phase 2 TARGET-D 203 Trial of VS-7375 for Metastatic Colorectal Cancer

TARGET-D 203 trial to evaluate VS-7375 both as monotherapy and in combination with cetuximab or panitumumab in previously treated metastatic colorectal...

July 30, 2026 | Thursday | News
Takeda Reported Phase 3 Zasocitinib Data Showing Strong Skin Clearance in Plaque Psoriasis

Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and pote...

July 30, 2026 | Thursday | News
AGC Biologics Secures Multi-Year Commercial Manufacturing Agreement for Yokohama Facility

Reached a long-term business cooperation with a large pharmaceutical company to help it promote production licensing and commercial supervision and app...

July 30, 2026 | Thursday | News
Basilea Secures Additional USD 30 Million BARDA Funding for Phase 3 Antifungal Program

Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bac...

July 29, 2026 | Wednesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close